RadNet, Inc.

Valuation Analysis

About the Company

RadNet, Inc., together with its subsidiaries, provides outpatient diagnostic imaging services in the United States and internationally. The company operates in two segments, Imaging Centers and Digital Health. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services. The company also develops and sells computerized systems that distribute, display, store, and retrieve digital images; picture archiving communications systems and related services; and develops and deploys AI suites to enhance radiologist interpretations of breast, lung, and prostate images, as well as solutions for prostate cancer scr

RadNet, Inc. Stock at a Glance

RadNet, Inc. (RDNT) is currently trading at $56.71 with a market capitalization of $4.5B. The 52-week range spans from $50.76 to $85.84; the current price is 33.9% below the yearly high. Year-over-year revenue growth stands at +22.1%.

💰 Dividend

RadNet, Inc. currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Analyst Rating

8 analysts rate RadNet, Inc. (RDNT) on consensus: Strong Buy. The average price target is $89.75, implying +58.26% from the current price. Analyst price targets range from $65.00 to $100.00.

RadNet, Inc.: The Investment Case in Detail

RadNet, Inc. (RDNT) operates in the Healthcare — specifically Diagnostics & Research — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

The Bull Case

Revenue is growing at a healthy 22.1% pace year-over-year, suggesting the business model continues to find new customers and pricing power. Wall Street consensus sits at Strong Buy with an average price target implying roughly 58.26% upside from current levels — analyst sentiment is firmly constructive.

The Bear Case

Net margins remain negative, meaning every euro of revenue is still producing losses — the path to profitability is the central question for shareholders. Short interest sits at 13.8% of float — a meaningful contingent of professionals is positioned for the share to fall, which deserves attention even if their thesis may turn out to be wrong.

Valuation in Context

With a PEG ratio of 0.96, the price-to-earnings multiple is actually below the company's growth rate — classic value-meets-growth territory that Peter Lynch would have called a 'GARP' opportunity.

What to Watch Next

• The price sits in the lower quartile of the 52-week range — value hunters often start scaling in around this zone if fundamentals hold.
• The analyst consensus price target implies 58.26% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.

Investment Thesis: Strengths & Weaknesses

Technical Snapshot

The price is in a transition zone relative to the moving averages — no clear signal.

Risk Profile

The data points to market-like volatility, elevated short interest (13.8%), higher leverage relative to equity.

Trading Data

Related Stocks in the Same Sector

Where can I buy RadNet, Inc.?

Compare top-rated brokers — low fees, trusted providers, fully regulated.